Novacyt Sa Stock Current Ratio

NVYTF Stock  USD 0.63  0.02  3.28%   
Novacyt SA fundamentals help investors to digest information that contributes to Novacyt SA's financial success or failures. It also enables traders to predict the movement of Novacyt Pink Sheet. The fundamental analysis module provides a way to measure Novacyt SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novacyt SA pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novacyt SA Company Current Ratio Analysis

Novacyt SA's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Novacyt SA Current Ratio

    
  4.66 X  
Most of Novacyt SA's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novacyt SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, Novacyt SA has a Current Ratio of 4.66 times. This is 60.14% higher than that of the Healthcare sector and 37.06% higher than that of the Medical Devices industry. The current ratio for all United States stocks is 115.74% lower than that of the firm.

Did you try this?

Run USA ETFs Now

   

USA ETFs

Find actively traded Exchange Traded Funds (ETF) in USA
All  Next Launch Module

Novacyt Fundamentals

About Novacyt SA Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novacyt SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novacyt SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novacyt SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Novacyt Pink Sheet

Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.